Stocks · News reference
Nexentis Technologies Inc. announced that its subsidiary, MitoCareX Bio Ltd., has finished the first computational screening phase of its drug-discovery collaboration with AI research lab Boltz, PBC.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-19 AccNo: 0001493152-26-047578 Size: 208 KB Item 3.02: Unregistered Sales of Equity Securities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
The transition is designed to provide MitoCareX with a secure and flexible computing environment for its computational activities and evolving drug discovery requirements. The infrastructure deployment is expected to